Zevra Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Zevra Therapeutics, Inc. (ZVRA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Zevra Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.97M, a 20.50% increase year-over-year.
- Zevra Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.10M, a 0.32% decline year-over-year.
- Zevra Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.77M, a 55.51% decline year-over-year.
- Zevra Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.46M, a 8.33% decline year-over-year.
- Zevra Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $12.63M, a 15.24% decline from fiscal 2024.
- Zevra Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $14.91M, a 150.35% increase from fiscal 2023.
- Zevra Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $5.95M, a 38.66% increase from fiscal 2022.
- Zevra Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.29M, a 76.27% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.97M 10-Q · filed 2026-08-05 | $6.07M derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $3.10M 10-Q · filed 2026-08-05 | ||||
| 2025-12-31 | $12.63M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $2.77M 10-Q · filed 2025-11-05 | $5.24M derived: sum of 2 quarters · filed 2026-08-05 | $8.35M derived: sum of 3 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $2.46M 10-Q · filed 2026-08-05 | $5.58M derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $3.12M 10-Q · filed 2026-08-05 | $3.05M 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $14.91M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $6.23M 10-Q · filed 2025-11-05 | $6.14M 10-Q · filed 2024-11-13 | $8.92M derived: sum of 2 quarters · filed 2025-11-05 | $11.11M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $2.69M 10-Q · filed 2025-11-05 | $2.63M 10-Q · filed 2024-08-14 | $4.88M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $2.19M 10-Q · filed 2025-11-05 | $2.12M 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $5.95M 10-K · filed 2025-03-12 | ||||
| 2023-09-30 | $1.44M 10-Q · filed 2024-11-13 | $1.39M 10-Q · filed 2023-11-07 | $3.59M derived: sum of 2 quarters · filed 2024-11-13 | $4.54M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $2.15M 10-Q · filed 2024-11-13 | $1.10M 10-Q · filed 2023-08-14 | $3.10M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $945.00K 10-Q · filed 2024-11-13 | $591.00K 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $4.29M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $911.00K 10-K · filed 2024-04-01 | $2.42M derived: sum of 2 quarters · filed 2024-04-01 | $3.34M derived: sum of 3 quarters · filed 2024-04-01 | ||
| 2022-06-30 | $1.51M 10-K · filed 2024-04-01 | $2.43M derived: sum of 2 quarters · filed 2024-04-01 | |||
| 2022-03-31 | $918.00K 10-K · filed 2024-04-01 | ||||
| 2021-12-31 | $2.44M 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | $620.00K 10-Q · filed 2022-11-10 | $938.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.61M derived: sum of 3 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $318.00K 10-Q · filed 2022-11-10 | $993.00K derived: sum of 2 quarters · filed 2022-11-10 | |||
| 2021-03-31 | $675.00K 10-Q · filed 2022-11-10 | ||||
| 2020-12-31 | $2.49M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $385.00K 10-Q · filed 2021-11-10 | $1.00M derived: sum of 2 quarters · filed 2021-11-10 | $2.03M derived: sum of 3 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $620.00K 10-Q · filed 2021-11-10 | $1.65M derived: sum of 2 quarters · filed 2021-11-10 | |||
| 2020-03-31 | $1.03M 10-Q · filed 2021-11-10 | ||||
| 2019-12-31 | $4.41M 10-K · filed 2021-03-12 | ||||
| 2019-09-30 | $1.06M 10-Q · filed 2020-10-30 | $2.37M derived: sum of 2 quarters · filed 2020-10-30 | $3.66M derived: sum of 3 quarters · filed 2020-10-30 | ||
| 2019-06-30 | $1.32M 10-Q · filed 2020-10-30 | $2.61M derived: sum of 2 quarters · filed 2020-10-30 | |||
| 2019-03-31 | $1.29M 10-Q · filed 2020-10-30 | ||||
| 2018-12-31 | $6.50M 10-K · filed 2020-02-28 | ||||
| 2018-09-30 | $2.59M 10-Q · filed 2019-11-14 | $3.96M derived: sum of 2 quarters · filed 2019-11-14 | $5.25M derived: sum of 3 quarters · filed 2019-11-14 | ||
| 2018-06-30 | $1.38M 10-Q · filed 2019-11-14 | $2.66M derived: sum of 2 quarters · filed 2019-11-14 | |||
| 2018-03-31 | $1.28M 10-Q · filed 2019-11-14 | ||||
| 2017-12-31 | $4.56M 10-K · filed 2019-03-01 | ||||
| 2016-12-31 | $6.60M 10-K · filed 2018-03-30 | ||||
| 2015-12-31 | $2.37M 10-K · filed 2018-03-30 | ||||
| 2014-12-31 | $214.00K 10-K · filed 2017-03-10 | ||||
| 2013-12-31 | $134.00K 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |